梅州玻尿酸填充眉弓(梅州怀孕做打胎手术费用) (今日更新中)

WASHINGTON, Aug. 3 (Xinhua) -- The annual number of new HIV infections in the United States was relatively stable at approximately 50,000 new infections each year between 2006 and 2009, the Centers for Disease Control and Prevention's first multi- year estimates from its national HIV incidence surveillance find.However, HIV infections increased among young men who have sex with men (MSM) between 2006 and 2009, driven by alarming increases among young, black MSM -- the only subpopulation to experience a sustained increase during the period.According to the new estimates, there were 48,600 new HIV infections in the United States in 2006, 56,000 in 2007, 47,800 in 2008 and 48,100 in 2009. The multi-year incidence estimates allow for a reliable examination of trends over time. They reveal no statistically significant change in HIV incidence overall from 2006 to 2009, with an average of 50,000 for the four-year period. In 2009, the largest number of new infections was among white MSM (11,400), followed closely by black MSM (10,800). Hispanic MSM (6, 000) and black women (5,400) were also heavily affected.The new estimates were published Wednesday in the on-line scientific journal PLoS ONE."More than 30 years into the HIV epidemic, about 50,000 people in this country still become infected each year. Not only do men who have sex with men continue to account for most new infections, young gay and bisexual men are the only group in which infections are increasing, and this increase is particularly concerning among young African American MSM," said CDC Director Thomas Frieden. " HIV infections can be prevented. By getting tested, reducing risky behaviors, and getting treatment, people can protect themselves and their loved ones."

SYDNEY, June 29 (Xinhua) -- A type of dried seaweed sold in Asian food supermarkets in Australia has been recalled after it was found to have high levels of iodine dangerous to pregnant women, local media reported on Wednesday.Food Standards Australia New Zealand (FSANZ) has ordered the recall of Wang Dried Kelp Varech Speche, a Korean brand of the dried seaweed, according to Australian Associated Press (AAP).It has been available in Asian grocery stores and restaurants in the Brisbane and Gold Coast areas of Queensland."The product contains high levels of naturally occurring iodine," FSANZ said in a statement."Regular consumption of these products may cause health problems in some people including pregnant and breastfeeding women."FSANZ said consumers concerned about their health should seek medical advice and should return the products to the place of purchase for a full cash refund.

XICHANG, Sichuan, Aug. 12 (Xinhua) -- China launched a communications satellite PAKSAT-1R for Pakistan at 0:15 a.m. Friday from the Xichang Satellite Launch Center in southwest China's Sichuan Province.The satellite was carried by a Long March-3B carrier rocket, according to the launch center. It is China's first in-orbit delivery to Asian customers and also the first commercial satellite export to international users this year.According to statistics from the control center, the satellite successfully separated from its carrier rocket and entered geostationary transfer orbit as scheduled, 26 minutes after being launched.PAKSAT-1R will provide a range of services, including broadband Internet, telecom and broadcasting, covering some regions of Europe, South Asia, the Middle East, and the eastern Africa.The contract for the PAKSAT-1R was signed in 2008 between China Great Wall Industry Corporation and the Space and Upper Atmosphere Research Commission of Pakistan.China and Pakistan share a long history of space technology cooperation. Pakistan's first low-orbit satellite, BADR-A, was launched by China in 1990 with Long March 2E rocket.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, August 3 (Xinhuanet) -- Women who experience any form of gender-based violence are at greater risk of mental health disorders and related dysfunction and disability, according to Australian researchers Wednesday.Those who'd been through at least one form of this abuse -- which includes intimate partner violence, rape, sexual assault, or stalking -- were almost three times more likely to experience a mental health condition than those who were never victimized, according to Susan Rees, PhD of the University of New South Wales in Sydney, Australia, and her colleagues.Those who'd experienced three or four forms had an 11-fold greater risk, reported in the Aug. 3 issue of the Journal of the American Medical Association.The study "reveals a pattern of social disadvantage, disability, and impaired quality of life among women who have experienced gender-based violence," the researchers wrote.

来源：资阳报